I am writing to express my concern about the potential loss of access to compounded GLP-1 treatments, which hundreds of thousands of Americans have found to be essential for managing their health.

Due to affordability and availability issues, patients have relied on compounded GLP-1/GIP through Morph as an alternative to the brand-name medications from Eli Lilly and Novo Nordisk. If the FDA moves forward with restricting compounded GLP-1s, patients will be faced with the difficult choice of either spending significantly more money on name-brand products or forgoing a treatment that has been life-changing.

Compounded GLP-1s are not just an alternative—they are essential medications for patients who rely on them to manage their health safely and effectively. Restricting access to compounded GLP-1s would undermine the health of patients who have no other viable options.

I ask you to consider the real, life-changing impact of these treatments. Please ensure that patients continue to have access to compounded GLP-1s as a critical part of health management. I hope that the administration listens to the voices of those who support and depend on this medication.

Thank you for your attention to this matter.